Back to Browse Journals » Biologics: Targets and Therapy » Volume 3

Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia

Authors Eric Cheung, Howard A Liebman

Published Date January 2009 Volume 2009:3 Pages 57—62

DOI http://dx.doi.org/10.2147/BTT.S3166

Published 8 January 2009

Eric Cheung, Howard A Liebman

Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California-Keck School of Medicine, Los Angeles, CA, USA

Abstract: Immune thrombocytopenia (ITP) is an acquired bleeding autoimmune disorder characterized by a markedly decreased blood platelet count. The disorder is variable, frequently having an acute onset of limited duration in children and a more chronic course in adults. A number of therapeutic agents have demonstrated efficacy in increasing the platelet counts in both children and adults. Anti-RhD immunoglobulin (anti-D) is one such agent, and has been successfully used in the setting of both acute and chronic immune thrombocytopenia. In this report we review the use of anti-D in the management of ITP. While the FDA-approved dose of 50 mg/kg has documented efficacy in increasing platelet counts in approximately 80% of children and 70% of adults, a higher dose of 75 μg/kg has been shown to result in a more rapid increase in platelet count without a greater reduction in hemoglobin. Anti-D is generally ineffective in patients who have failed splenectomy. Anti-RhD therapy has been shown capable of delaying splenectomy in adult patients, but does not significantly increase the total number of patients in whom the procedure can be avoided. Anti-D therapy appears to inhibit macrophage phagocytosis by a combination of both FcR blockade and inflammatory cytokine inhibition of platelet phagocytosis within the spleen. Anti-RhD treatment is associated with mild to moderate infusion toxicities. Rare life-threatening toxicities such as hemoglobinuria, acute renal failure and disseminated intravascular coagulation have been reported. Recommendations have been proposed to reduce the risk of these complications. Anti-D immunoglobulin can be an effective option for rapidly increasing platelet counts in patients with symptomatic ITP.

Keywords: immune thrombocytopenia, RhD immunoglobulin

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Adverse reaction to ceftriaxone in a 28-day-old infant undergoing urgent craniotomy due to epidural hematoma: review of neonatal biliary pseudolithiasis

Bartkowska-Śniatkowska A, Jończyk-Potoczna K, Zielińska M, Rosada-Kurasińska J

Therapeutics and Clinical Risk Management 2015, 11:1035-1041

Published Date: 2 July 2015

How can undergraduate ophthalmology teaching be improved?

Ah-kee EY, Khan AA

Advances in Medical Education and Practice 2015, 6:469-470

Published Date: 25 June 2015

Roles of dopamine receptors and their antagonist thioridazine in hepatoma metastasis

Lu M, Li J, Luo Z, Zhang S, Xue S, Wang K, Shi Y, Zhang C, Chen H, Li Z

OncoTargets and Therapy 2015, 8:1543-1552

Published Date: 22 June 2015

Matrix-induced autologous chondrocyte implantation for the treatment of chondral defects of the knees in Chinese patients

Zhang ZW, Zhong X, Ji HR, Tang ZB, Bai JP, Yao MM, Hou JL, Zheng MH, Wood D, Sun JZ, Zhou SF, Liu AB

Drug Design, Development and Therapy 2014, 8:2439-2448

Published Date: 5 December 2014

Release of tissue inhibitor of metalloproteinase-2 from alginate microcapsule encapsulating genetically engineered cells

Kim YS, Jeong YI, Jin SG, Pei J, Wen M, Kim IY, Moon KS, Jung TY, Ryu HH, Jung S

International Journal of Nanomedicine 2013, 8:4351-4359

Published Date: 6 November 2013

Supramolecular micellar nanoaggregates based on a novel chitosan/vitamin E succinate copolymer for paclitaxel selective delivery

Lian H, Sun J, Yu YP, Liu YH, Cao W, Wang YJ, Sun YH, Wang SL, He ZG

International Journal of Nanomedicine 2011, 6:3323-3334

Published Date: 12 December 2011

Regulatory mechanisms of apoptosis in regularly dividing cells

Ribal S Darwish

Cell Health and Cytoskeleton 2010, 2:59-68

Published Date: 17 August 2010